First published 9/28/2026, 9:59:15 AM · Last updated 9/28/2026, 9:59:15 AM

Impact of different TP53 mutation subtypes on response and outcome in advanced lung adenocarcinoma receiving first-line immunotherapy or chemo-immunotherapy

Journal article reporting an analysis of how various TP53 mutation subtypes relate to treatment response and outcomes in advanced lung adenocarcinoma patients treated with first-line immunotherapy or chemo-immunotherapy, published 2026-09-01. The provided source excerpt includes only publisher and content type metadata and no additional methodological or result details.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 6/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 6/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

Results could affect clinical understanding of mutation-specific treatment responses in advanced lung adenocarcinoma.

Sources

Impact of different TP53 mutation subtypes on response and outcome in advanced lung adenocarcinoma receiving first-line immunotherapy or chemo-immunotherapy

Report an issue